IL6 and arthritic joint disease: The IL-6 receptor antagonist tocilizumab is reported to be effectiveness against ICI-induced arthritis.[7] Further, IL-6 has been shown to promote cancer occurrence, progression, and metastasis, but IL-6 inhibition impedes cancer progression.[20,21] The pathophysiology of irAEs of IL-6 receptor antagonists is thought to be mediated by the suppression of T helper 17 cells.